Document Detail

Validity of the disease activity score in undifferentiated arthritis.
MedLine Citation:
PMID:  20506371     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To study whether the Disease Activity Score (DAS) is a valid measure of disease activity in undifferentiated arthritis (UA). METHODS: Data from a randomized, double-blind, placebo-controlled trial of methotrexate (MTX) and placebo involving 110 patients with UA were used. Data included baseline and 3, 6, 9, and 12 months, as well as diagnosis at 18 months. Validity of the DAS was analyzed using factor analysis, correlations with disease activity variables, correlations with changes in disability and joint damage, differences in DAS between diagnoses, and detecting the difference between placebo and MTX. RESULTS: Three disease activity factors were retrieved from the disease activity variables: patient reported outcomes, tender and swollen joints, and acute phase reactants. The DAS had its highest correlations (r > 0.77) with tender joint counts, followed by swollen joint counts (r > 0.63) and patient reported outcomes (r > 0.30), but the DAS correlated less with C-reactive protein levels (r = 0.32). Over time, the DAS was related to the Health Assessment Questionnaire response with an odds ratio of 4.1 (95% confidence interval 2.1-8.0), but not with change in joint damage. At 18 months, the mean DAS was 2.6 for rheumatoid arthritis patients, 2.2 for UA patients, and 1.9 for patients in remission (P = 0.001). The DAS discriminated better than all single variables between MTX and placebo, with a Guyatt's effect size of 0.89. CONCLUSION: The DAS appears to be a reasonably valid measure of disease activity for use in UA clinical trials.
Jaap Fransen; Karen Visser; Henrike van Dongen; Tom Huizinga; Piet L C M van Riel; Désirée M van der Heijde
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Validation Studies    
Journal Detail:
Title:  Arthritis care & research     Volume:  62     ISSN:  2151-4658     ISO Abbreviation:  Arthritis Care Res (Hoboken)     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-08     Completed Date:  2010-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101518086     Medline TA:  Arthritis Care Res (Hoboken)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1392-8     Citation Subset:  IM    
Radboud University Nijmegen Medical Centre, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis / diagnosis*,  drug therapy,  pathology*
Arthritis, Rheumatoid / diagnosis,  drug therapy,  pathology
Disease Progression
Double-Blind Method
Methotrexate / therapeutic use
Middle Aged
Severity of Illness Index*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy of traditional and biological agents in different clinical phenotypes of adult-onset Still'...
Next Document:  Contribution of myeloid dendritic cells to type I interferon-induced cytokines and chemokines.